Elsevier and European Alliance of Associations for Rheumatology announce new partnership

The European Alliance of Associations for Rheumatology (EULAR) announces a new partnership with Elsevier, a global leader in information and analytics, to publish its flagship scientific journal, Annals of the Rheumatic Diseases (ARD). The journal will be hosted on Elsevier’s leading online platform, ScienceDirect, beginning January 2025

“We are delighted that our flagship journal will continue its successful journey with the world's largest publisher and feel that this partnership will equip us ideally for the challenges of the future,” said Professor Daniel Aletaha, EULAR President.

Professor Josef Smolen, ARD Editor-in-Chief, adds: “Authors, researchers and readers can expect a seamless transition while maintaining the journal's high standards and commitment to excellence.”

Originally published in 1939, ARD has always strived for excellence in research advances and novel clinical insights. Thus, it continues to be the leading rheumatology journal publishing high-quality scientific papers, original research, reviews, recommendations, viewpoints, and more. Basic, clinical, and translational scientific research across the inflammatory and non-inflammatory musculoskeletal conditions is part and parcel of this spectrum.

The journal’s authors, reviewers and editors volunteer their time and expertise to contribute and disseminate this important scientific information to the international research community with a hybrid subscription-based model. Its current (2023) Impact Factor of 20.3 places it second overall in the Rheumatology subject category and first among the journals publishing original research advances. The 2023 CiteScore of 35 places it in the #1/73 (99^th percentile) position in the category Medicine/Rheumatology.

“We are very honoured to be chosen as the publishing partner for EULAR. Elsevier is committed to providing EULAR with a trusted platform, addressing customer needs, and providing insight through data analytics. Our collaboration will further support both organisations’ efforts to improve health outcomes”, stated Carl Schwarz, Senior Vice President, Health and Medical Sciences at Elsevier. “ARD is a hugely respected journal in the rheumatology field and will be a great fit with our rheumatology portfolio. We are very proud that EULAR has chosen to partner with us and look forward to helping them and ARD transition to Elsevier,” added Tanya Wheatley, Elsevier’s Executive Publisher for Rheumatology.

About the European Alliance of Associations for Rheumatology (EULAR)

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

エルゼビアについて エルゼビアは、科学情報と分析を牽引するグローバル企業として、研究者や医療従事者が社会の利益のために科学を進歩させ、医療成果を向上させることを支援しています。我々は信頼できるエビデンスベースのコンテンツと高度なAI対応デジタルテクノロジーに基づくソリューションにより、インサイトと重要な意思決定を促進することでこれを実現しています。

エルゼビアは、140 年以上にわたり研究および医療コミュニティの活動を支援してきました。全世界で 2,500 人以上の技術者を含む 9,500 人の従業員がおり、重要な職務における研究者や、図書館員、アカデミックリーダー、資金提供者、政府機関、R&D 関連企業、医師、看護師、将来の医療従事者や教育者を支援することに従事してきました。2,900 誌以上の科学ジャーナルと代表的な参考文献には、Cell Press、The Lancet、Gray's Anatomy など、各分野の主要なタイトルを含みます。 エルゼビア・ファウンデーション 新しいタブ／ウィンドウで開くと共に、開発途上国および世界中の科学、研究、医療分野におけるインクルージョン＆ダイバーシティを推進するため、支援コミュニティと連携して活動しています。 エルゼビアは、プロフェッショナルおよびビジネス顧客向けの情報に基づく分析および意思決定ツールのグローバルプロバイダーである RELX 新しいタブ／ウィンドウで開くグループの一部です。業務内容やデジタルソリューション、コンテンツ詳細については、 www.elsevier.com/ja-jpをご参照ください。